


Certificate of Mailing:	
Date of Deposit: <u>February 1, 2006</u>	Label Number: <u>EV 768765350 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Elvis DeLaCruz Printed name of person mailing correspondence	 Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	SAINT-REMY et al.	Art Unit:	Not Yet Assigned
Serial No.:	Not Yet Assigned	Examiner:	Not Yet Assigned
Filed:	February 1, 2006	Customer No.:	21559
Title:	VARIABLE ANTIBODIES		

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Copies of a search report and communications from a foreign patent office in a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed with the application.

10/566851


If there are any charges or any credits, please apply them to Deposit Account No.

IAP20 Rec'd REGA TO 01 FEB 2006

03-2095.

Respectfully submitted,

Date: 1 February 2006



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/112001
	Serial No.	10/366851
	Applicant	SAINT-REMY et al.
	Filing Date	February 1, 2006
	Group	Not Yet Assigned
	IDS Filed	February 1, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 822 255 A2	02/04/98	EPO			
	WO 01/04269 A1	01/18/01	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	International Preliminary Report on Patentability (PCT/BE2004/000118) (2 December, 2005).					
	International Search Report (PCT/Be2004/000118) (mailed 2 February, 2005).					
	Kallas et al., "Epitope Specificity of Anti-FVIII Antibodies During Immune Tolerance Therapy with Factor VIII Preparation Containing von Willebrand Factor," <i>Thromb. Res.</i> 107:291-302 (2002).					
	Kato et al., "Activity Enhancement of a Lung Cancer-Associated Human Monoclonal Antibody HB4C5 by N-Deglycosylation," <i>Hum. Antibod. Hybridomas</i> 4:9-14 (1993).					
	Khurana et al., "The Variable Domain Glycosylation in a Monoclonal Antibody Specific to GnRH Modulates Antigen Binding," <i>Biochem. Biophys. Res. Commun.</i> 234:465-469 (1997).					
	Response to the Written Opinion (PCT/BE2004/000118) (22 April, 2005).					
	Sato et al., "Humanization of an Anti-Human IL-6 Mouse Monoclonal Antibody Glycosylated in its Heavy Chain Variable Region," <i>Hum. Antibod. Hybridomas</i> 7:175-183 (1996).					
	Singh et al., "Antithrombotic Effects of Controlled Inhibition of Factor VIII with a Partially Inhibitory Human Monoclonal Antibody in a Murine Vena Cava Thrombosis Model," <i>Blood</i> 99:3235-3240 (2002).					
	Wright et al., "Antibody Variable Region Glycosylation: Position Effects on Antigen Binding and Carbohydrate Structure," <i>EMBO J.</i> 10:2717-2723 (1991).					
	Written Opinion of the International Searching Authority (PCT/BE2004/000118) (2 February, 2005).					
	XP 002314129, Database BIOSIS, Accession No. PREV200400181239, Jacquemin et al., "Glycosylation of a Type 2 Factor VIII Inhibitor Determines its Maximum Level of FVIII Inhibition," <i>45th Annual Meeting of the American Society of Hematology</i> , San Diego, CA, USA, December 6-9, 2003 (Abstract).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						